Prognosis
J&J Pharma Executive Reveals Playbook for Standalone Drugmaker
- Jennifer Taubert reveals playbook for standalone drugmaker
- Drug franchise to realign focus, set sights on deals
This article is for subscribers only.
Johnson & Johnson will focus on developing drugs for conditions such as lung cancer and eye disease as it prepares to make its pharmaceutical and medical-devices business an independent entity.
The 135-year-old health giant faces its greatest-ever overhaul as it readies for a spin-out of its consumer unit, following a path trod by rivals such as GlaxoSmithKline Plc and Pfizer Inc. In her first-ever interview, Jennifer Taubert, J&J’s executive vice president and worldwide chairman of pharmaceuticals, told Bloomberg News that the company will invest in new areas of interest.